Please login to the form below

Not currently logged in

BMS' profit down, Lilly's up

Bristol-Myers Squibb has reported a drop in Q2 profit while Eli Lilly has announced a net income increase of 16 per cent for the quarter

Bristol-Myers Squibb (BMS) has reported a drop in second-quarter profit that the company attributes to the 2009 spin-off of its nutritionals unit. Profit was down by about 6 per cent compared to last year's second quarter, coming in at $927m, or 53 cents per share.

Revenue was up slightly, coming in at $4.77bn for the quarter, compared to $4.67bn in 2009's second quarter.

Eli Lilly and Company's second-quarter net income was up 16 per cent to $1.35bn, or $1.22 per share, compared to $1.16bn, or $1.06 per share, in the second quarter of 2009. Revenue was up 9 per cent to $5.75bn.

However, Lilly's good news was tempered by the fact that the numbers largely reflect robust sales of drugs that are due to go off patent in the coming years.

For example, antipsychotic Zyprexa (olanzapine) sales were up 5 per cent to $1.26bn and antidepressant Cymbalta (duloxetine) sales were up 17 per cent to $867.7m. Zyprexa is due to lose US patent protection next year, while Cymbalta will go off patent in 2013.

22nd July 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...